DSIP — delta sleep-inducing peptide — is one of the more enigmatic compounds in the research-peptide category. First isolated in 1977 from the cerebral venous blood of rabbits in slow-wave sleep, the nine-amino-acid sequence has been studied for almost five decades, yet the human evidence base is far smaller than the long timeline would suggest. This guide walks through what DSIP is, what the research literature actually shows, how Australian regulation classifies it, and which questions Australian researchers most commonly ask about it.
This article is a research-context overview only. It is not medical, therapeutic, or dosing advice. See the disclaimer at the end.
What DSIP is
DSIP is a nonapeptide — a chain of nine amino acids — with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was named for the experimental context in which it was discovered: rabbits in delta-wave sleep had elevated levels of this peptide in cerebral venous blood compared to awake controls. The naming reflects a correlation observed in 1977 rather than a confirmed mechanistic role. Subsequent decades of research have shown that the relationship between DSIP and slow-wave sleep is more complex than the original name implies, and the peptide turns up in multiple non-sleep-related research contexts.
Structurally, DSIP is small (molecular weight around 850 daltons) and amphipathic, which has implications for how it crosses biological membranes. Unlike many of the longer research peptides studied at Optic Labs — see our complete guide to peptides in Australia — DSIP's small size has been one reason researchers have explored alternative routes of administration including intranasal delivery in some study designs. The endogenous receptor for DSIP has not been definitively identified despite extensive investigation, which makes it pharmacologically unusual: most studied peptides have a well-characterised primary receptor target, but DSIP's mechanism remains an open research question.
The sleep research literature
Despite the name, the literature on DSIP and sleep is mixed. Early studies in the late 1970s and 1980s reported increases in slow-wave sleep duration in animal models when DSIP was administered, and a handful of small human studies in chronic insomnia populations reported subjective sleep improvements. However, larger and more rigorously controlled studies have produced inconsistent results, and several reviews from the 1990s and 2000s concluded that DSIP's effects on sleep architecture, when present, are modest and variable.
The mechanistic picture is similarly incomplete. DSIP has been shown in research contexts to interact with neuropeptide systems, modulate corticotropin-releasing-factor pathways, and influence circadian-rhythm-related signalling, but no single dominant pathway has emerged. This is markedly different from the GH-axis research peptides — CJC-1295 with Ipamorelin and Tesamorelin are examples — where the receptor targets and downstream pathways are well-characterised. DSIP's research literature is broader but shallower: many studies, many reported effects, but no consolidated mechanistic model.
Beyond sleep: other research directions
What is sometimes overlooked in summaries of DSIP is that the published literature extends well beyond the sleep context. DSIP has been studied for putative anti-stress effects in animal models, with research papers reporting reduced stress-induced behavioural changes following peptide administration. There is a thread of research examining DSIP's interactions with the hypothalamic-pituitary-adrenal axis, particularly with respect to cortisol modulation under stress conditions.
Other research directions include: investigations into DSIP's potential role in pain modulation in animal models; some early-stage work on antioxidant properties at the cellular level; and studies looking at DSIP in the context of opiate withdrawal symptom modulation. None of these research directions have produced large or definitive human trial data — the literature is dominated by small studies, animal work, and mechanistic explorations rather than phase 2/3 clinical trial evidence. For researchers comparing DSIP to other neuropeptides studied in cognitive or anxiolytic contexts, our coverage of Selank and the broader anxiolytic-peptide category provides relevant context.
Australian regulatory status
In Australia, DSIP is subject to the Therapeutic Goods Administration's regulatory framework that applies to research peptides generally. It is not an approved therapeutic product on the Australian Register of Therapeutic Goods (ARTG), and it is supplied for laboratory research use only. As with other research peptides, the Schedule 4 (Prescription Only Medicine) classification under the Poisons Standard applies to peptides that are intended for therapeutic use in humans; research-use supply operates under a separate framework where compounds are intended for in vitro and laboratory research and are not labelled or sold for human consumption.
For a longer treatment of the regulatory framework — including the distinctions between the ARTG, the Poisons Standard, and the Special Access Scheme — see our TGA compliance guide. Australian researchers and individuals should verify the current Poisons Standard listing before any acquisition or use; the regulatory landscape changes over time and the TGA periodically reviews scheduling of peptides and related compounds.
Quality, purity, and storage considerations for DSIP research
DSIP supplied for research is typically a lyophilised (freeze-dried) powder, reconstituted with bacteriostatic water for in vitro study or research handling. Like other lyophilised peptides, DSIP is generally stable when stored at refrigeration temperatures pre-reconstitution and remains stable in solution for shorter windows after reconstitution — typically several weeks under refrigeration, depending on the specific batch and bacteriostatic preservative. Purity verification via third-party HPLC and mass-spec testing is the standard expectation in research-supply contexts; Optic Labs publishes purity testing for all peptides supplied, and our DSIP 10mg product page lists current purity and batch documentation.
For researchers handling DSIP alongside other peptides in a research workflow, the peptide reconstitution calculator guide and general peptide storage guide cover the protocol-level considerations that apply to DSIP as they do to most lyophilised research peptides. DSIP's small molecular size does not change the fundamentals of cold-chain storage or aseptic reconstitution technique.
Frequently asked questions
What is DSIP and what is it used for in research?
DSIP is a nine-amino-acid peptide originally isolated from rabbits in slow-wave sleep in 1977. In research it is used as a tool compound for studying sleep architecture in animal models, hypothalamic-pituitary-adrenal axis modulation, and stress-response pathways. It has also appeared in research literature on pain modulation, antioxidant cellular effects, and opiate-withdrawal models. It is not an approved therapeutic product in Australia or in any major regulatory jurisdiction.
How does DSIP work?
The honest answer is that the mechanism remains an open research question. No single endogenous receptor for DSIP has been definitively identified despite decades of investigation. DSIP appears to interact with multiple neuropeptide and stress-axis systems in research contexts, including CRF pathways and circadian-rhythm-related signalling. This makes DSIP unusual among studied research peptides — most have a well-characterised primary receptor target, while DSIP's mechanism is best described as multi-pathway and incompletely mapped.
Does DSIP work for sleep in human studies?
The human research evidence is mixed. Early small studies in chronic insomnia populations reported subjective sleep improvements, but larger and more rigorously controlled studies have produced inconsistent results. Reviews of the literature have concluded that DSIP's effects on sleep architecture, where reported, are modest and variable. There is no large, definitive human clinical trial that establishes a clear sleep-promoting effect, and DSIP is not approved as a sleep medication in any major regulatory jurisdiction.
Is DSIP safe?
Safety data on DSIP in humans is limited because the human study base is small. Animal studies have generally reported low acute toxicity, and the small human studies that exist did not report significant safety signals — but the absence of large-scale safety data should not be confused with confirmed safety. As with any research peptide, the safety profile is bounded by the size and quality of the trials conducted, and DSIP has not been through the kind of large phase 3 trial programme that would yield a robust safety dataset. Research-use suppliers like Optic Labs supply DSIP for laboratory work, not for human use, precisely because that human safety dataset is incomplete.
Disclaimer
This article is for research and educational context only. DSIP supplied by Optic Labs is intended for laboratory and in vitro research use; it is not a therapeutic product and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease — including sleep disorders, stress, or any other condition. Nothing in this article is medical, therapeutic, dosing, or compliance advice. Australian regulations under the Therapeutic Goods Act and the Poisons Standard apply; researchers and individuals should verify current TGA and Poisons Standard listings before any acquisition. Speak with a qualified Australian medical practitioner about any health-related decision, including any questions about sleep, stress, or other health concerns.